Our CEO, Dr. Shlomi Madar, was invited to present at the NYU Langone Health Institute for Systems Genetics as part of its Nano Seminar Series. During the seminar, Dr. Madar presented SpotitEarly’s Bio-AI hybrid approach to breath-based cancer screening, explaining how trained canines and the LUCID platform work together to identify cancer signatures in breath samples. He also shared the journey from early research through our current U.S. clinical studies.

Dr. Madar was also invited to deliver a seminar at the Ernest Mario School of Pharmacy at Rutgers University, part of Rutgers Biomedical and Health Sciences. The invitation came from Tamara Minko, Distinguished Professor and Department Chair, a member of the Rutgers Cancer Institute of New Jersey and author of more than 400 peer-reviewed publications in journals including Nature Nanotechnology and Cancer Research.

Dr. Shlomi Madar participated in two HITLAB events in March. The first was an in-person networking evening in New York City, bringing together leaders across AI, healthcare, and digital health. The second was the HITLAB Breakthrough Alliance members-only webinar, where Dr. Madar presented SpotitEarly's Bio-AI Hybrid approach to breath-based cancer screening, covering the clinical data, the LUCID platform, and the company's path toward U.S. commercial availability.

Dr. Madar attended the Founders & Funders VC Reverse Pitch at the Jay Conference in New York City. The event flipped the traditional pitch format, with six venture capital firms, including RRE Ventures, Plum Alley, Forum Ventures, and Konvoy, taking the stage to present their investment theses directly to a room of founders. The evening provided direct insight into current funding priorities across the NYC venture landscape and an opportunity to connect with active investors in healthcare and technology.

SpotitEarly has launched its own podcast series, "The Long Game: Voices from the Healthfront" - a show dedicated to candid conversations at the intersection of health, science, and the future of diagnostics. Each episode features guests from across medicine, research, law, and technology, exploring the ideas and challenges shaping where healthcare is headed.

Our team joined Philadelphia's biotech community at the BioLabs space at The Curtis for an evening focused on scaling therapeutics through development. Events like these reflect our commitment to building within the broader biotech community as we approach our U.S. commercial launch. 

Our CEO Shlomi Madar Ph.D. pitched at the BioLabs Investor Day 2026 in Philadelphia. The day's pitches spanned oncology, neurodegenerative diseases, rare diseases, longevity, and aesthetics, covering medicines, modalities, devices, and diagnostics. A panel on academic partnerships for early-stage discovery and co-development. The conversation was directly relevant to how we build our own clinical and research collaborations.

Our COO and co-founder Udi Bobrovsky pitched SpotitEarly at the HealthTech and Life Sciences Track of Tech Week Miami 2026 this week. The track brought together more than 2,000 attendees, 150 speakers, and top investors from across the global tech ecosystem. Udi walked the room through our Bio-AI Hybrid platform for non-invasive, multi-cancer detection through breath analysis, and where we stand on the path to U.S. commercial launch.

Dr. Madar attended a private breakfast hosted by Forum Ventures, Brown Rudnick, and Mount Sinai Health System. A panel of clinicians, investors, and founders covered both the science of longevity (inflammation, sleep, and exercise as today's most tangible health levers) and the systems side (who pays for longevity care, and how data integration shapes patient experience). The conversation reinforced the strategic position of early detection in the broader longevity landscape.

Dr. Madar delivered the keynote at the HITLAB Innovators Summit, titled "Breath-Based Cancer Screening: Building the Next Scalable Early Detection Platform." The talk covered why breath is the right substrate for early detection, where the hard problems sit (sample integrity, signal interpretation, clinical workflow), and how LUCID, our Bio-AI Hybrid platform, is engineered to scale.